The Clocks Go Back This Weekend. Here Is What the Evidence Says It Does to Us.

In the early hours of Sunday 25 October, clocks across the UK will go back an hour as British Summer Time comes to an end. For most people this means an extra hour in bed and lighter mornings, paid for with afternoons that now darken well before the end of the working day. It also revived, as it does every autumn, the argument over whether changing the clocks twice a year is quietly harming us. The research behind that argument has moved on considerably. A long-repeated link to heart attacks has weakened under much larger datasets, the spike in road collisions turns out to be tangled up with the weather, and a 2025 modelling study suggests the real cost may lie less in the switch itself than in months of living out of step with our body clocks.

The Heart Attack Link That Has Not Held Up

The claim that changing the clocks triggers heart attacks rests largely on studies published over the past two decades. In 2019, researchers led by Roberto Manfredini brought seven of them together in the first meta-analysis on the subject, published in the Journal of Clinical Medicine and covering more than 115,000 people. Across the two weeks following either clock change, the odds of an acute heart attack were around 3 per cent higher than in control periods. Split by season, though, the picture changed: the rise was concentrated after the spring change, when an hour of sleep is lost, while the week after the autumn change looked no different from comparison periods. The authors also noted that further studies fully adjusting for confounding factors were needed to confirm the findings.

A much larger study has since cast doubt on even the spring effect. Researchers at Duke University, writing in JAMA Network Open in September 2025, analysed 168,870 patients admitted with a heart attack to 1,124 US hospitals between 2013 and 2022, comparing the week before, the week of and the week after both the spring and autumn transitions. They found no significant differences in heart attack incidence, nor in in-hospital outcomes such as death and stroke, for either change. The one marked increase came in the week after the spring 2020 transition, which coincided with the start of the Covid-19 pandemic. The dataset also included hospitals in Arizona and Hawaii, which do not change their clocks at all. Lead author Jennifer Rymer described it as “the most comprehensive look we’ve had at the relationship between DST and heart health.” It is a US study, but its scale makes it difficult to treat the older heart attack findings as settled.

On the Roads, Darkness and Weather Arrive Together

The road safety evidence is more consistent, but harder to pin on the clocks alone. An RAC Foundation analysis of six years of police data for Great Britain found an average of 278 more personal injury collisions in the two weeks after the autumn clock change than in the two weeks before, roughly 20 extra a day, with three quarters of them happening in the afternoon, the part of the day the change makes darker. The same analysis found, however, that collisions in which the weather was recorded as adverse rose by a similar proportion, and that after the clocks go forward in spring, morning injury collisions actually fall, by an average of 221 over the following fortnight, even though mornings become darker. Steve Gooding, director of the RAC Foundation, summed up the conclusion: “Every year at about this time there are calls to abandon the spring forward, fall-back rhythm of daylight savings time, but our work suggests that it’s darker days and winter weather together that cause the spike in road safety risk.”

That has not ended the debate. The Royal Society for the Prevention of Accidents has campaigned since the 1960s for the autumn change to be scrapped, pointing to a three year experiment that began in 1968, when Britain put its clocks forward in March and did not put them back again until October 1971.

The Case Against the Switch Itself

The most significant recent contribution shifts attention away from the days immediately after a clock change altogether. In a study published in the Proceedings of the National Academy of Sciences on 15 September 2025, Lara Weed and Jamie Zeitzer of Stanford University modelled how three policies, permanent standard time, permanent daylight saving time and twice-yearly switching, would affect circadian rhythms across the contiguous United States, then compared the resulting circadian burden against county-level health data from the Centers for Disease Control and Prevention.

Switching twice a year produced the greatest burden on the body clock. Permanent standard time, which prioritises morning light, came out best, with the model estimating a fall in obesity prevalence of 0.78 percentage points, around 2.6 million fewer people, and in stroke prevalence of 0.09 percentage points, around 300,000 fewer cases. Permanent daylight saving time also improved on the current arrangement, but by about two thirds as much. “We found that staying in standard time or staying in daylight saving time is definitely better than switching twice a year,” Zeitzer said. The estimates come from modelling under idealised light exposure conditions rather than from a trial, and from US data rather than British, but they frame the question differently: not whether one weekend is risky, but whether months of mismatch between the clock and the sun carry a cost. In UK terms, permanent standard time would mean staying on Greenwich Mean Time all year round.

One Hour, Three Different Answers

Put together, these three strands point in noticeably different directions. The acute heart attack risk that once dominated coverage has weakened as datasets have grown, the post-change rise in road collisions is real but shares the blame with autumn weather, and the strongest current argument against changing the clocks concerns long-term circadian misalignment rather than any single weekend. None of this settles what Britain should do, and the evidence on whether lighter mornings or lighter evenings serve people best is still being argued over. What has changed is the quality of the question. The hour went back on Sunday as it always does. The research on what that hour actually costs is considerably more precise than it was.

Sources: Journal of Clinical Medicine (Manfredini et al, 2019); JAMA Network Open (Rymer et al, 2025); Duke University School of Medicine; RAC Foundation; Royal Society for the Prevention of Accidents; Proceedings of the National Academy of Sciences (Weed and Zeitzer, 2025); Stanford Medicine.

Author

Leave A Comment

Graham Combe

Strategic Consultant,
Life Sciences Week
+44 (0) 121 227 4156
[email protected]

Bio

Graham Combe is an experienced strategic consultant, relationship builder, and entrepreneur in the global life sciences sector. He holds a BSc (Hons) in Chemistry from University College London (UCL) and spent over a decade with Nature, where he pioneered key initiatives such as Nature’s BioPharma Dealmakers and Nature’s SciCafe.

In May 2011, he founded Biosell UK, a consulting and event management firm that collaborates with global life science publishers, event organizations, and marketing partners. Beyond BioSell, Combe is the founder or co-founder of several prominent networking and thought-leadership platforms, including #BiotechBuddies, #coffeebuddies, the #AgileLeaders Forum, and the Creative Disruption Forum—the latter three events co-hosted with his business partner, Professor Tony Sedgwick.

Specializing in the early-to-mid stages of drug development (from pre-clinical research through Phase 3 and clinical proof-of-concept), Graham focuses on facilitating forums to promote peer-to-peer discussion, strategic growth, investment and meaningful connections between biotech innovators, investors, and industry service providers.

Apply for a complimentary Conference Day VIP Pass

Apply for a complimentary Conference Day VIP Pass

Complimentary Conference Day VIP Passes are reserved for senior leaders and decision-makers with influence over purchasing, commissioning, investment or technology advancements and adoption across UK life sciences.

A Conference Day VIP Pass includes:

  • Complimentary access-all-areas to the Launch Day Conference
  • Access to the dedicated VIP green room alongside Conference speakers
  • Access to all general keynote, panel and programme sessions
  • Curated networking opportunities
  • Opportunities to meet conference speakers and other approved VIP attendees

The VIP Pass applies to the Launch Day Conference only. It does not include admission to the Life Sciences Week Gala Dinner or other separately ticketed events.

Applications are reviewed individually and submitting this form does not guarantee a complimentary pass. To maintain a balanced, high-quality audience, we may limit the number of VIP Passes issued to any one organisation.

    First Name *

    Last Name *

    Work Email Address *

    Telephone Number *

    Job Title *

    Organisation *

    LinkedIn

    Organisation Information

    Which best describes your organisation? *


    If other, please specify

    Which best describes your level of seniority? *

    If other, please specify

    Which areas are you responsible for or directly involved in? *

    If other, please specify

    What best describes your role in purchasing, investment, commissioning or adoption decisions? *

    Attendance Information

    Briefly, what is the number one thing you are hoping to get out of attending Life Sciences Week 2026? *

    Final Confirmation

    Is your role primarily focused on selling products or services, consultancy, account management or business development? *

    Please Confirm *

    I understand that VIP applications are subject to review and approval.
    I understand that the complimentary VIP Pass covers the Life Sciences Week Launch Day Conference only and does not include the Gala Dinner Awards or other separately ticketed events.
    The information supplied in this application is accurate.

    Shabna Raja

    Advisory Partner,
    Life Sciences Week
    +44 (0) 121 227 4156
    [email protected]

    Bio

    Shabna Raja is a senior leader in enterprise transformation within Life Sciences, with over 20 years’ experience spanning pharma, consumer health and large-scale digital programmes.

    She specialises in bridging strategy and execution – helping organisations translate AI, data and digital innovation into tangible business outcomes. Her work focuses on complex transformation
    initiatives across commercial, data and operating model domains within regulated environments.

    Shabna spent seven years at GSK, where she played a key role in transformation programmes, including as part of the Consumer Health joint venture with Pfizer — one of the most significant integrations in the sector. This experience provided her with deep expertise in  organisational change, integration and operating model evolution at global scale.

    More recently, she has spent over three years working closely with Haleon through a strategic
    services partnership, leading enterprise client engagement and managing a multi-million-pound account while supporting transformation across a newly independent global organisation.

    Her experience spans the end-to-end life sciences value chain, including R&D, commercial, supply chain and patient engagement, giving her a holistic perspective on how technology and transformation can unlock value across the industry.

    Amjad Khan

    Executive Partner,
    Life Sciences Week
    +44 (0) 121 227 4156
    [email protected]

    Bio

    Amjad Khan is a UK-based entrepreneur, AI strategist, and senior technology leader with over 15 years of experience at Pfizer, where he held multiple leadership roles across digital strategy and transformation. As Global Digital Client Partner, he was responsible for digital strategy and execution across Global Business Units covering Vaccines, Hospital, and Medical Affairs. Most notably, he led the commercial launch for the Covid franchise transforming and accelerating the model for how new medicines are brought to market.

    Following his tenure at Pfizer, Amjad channelled his expertise into building at the frontier of AI. His work spans AI leadership, stakeholder engagement, and agile delivery helping organisations adopt and scale emerging  technologies to drive meaningful outcomes.

    Dr. Richard Fallon | Business Consultant | WM Life Sciences

    Dr. Richard Fallon

    Co Founder, Life Sciences Week 
    +44 (0) 121 227 4156
    [email protected]

    Bio

    Dr Richard Fallon is an entrepreneur and ecosystem builder who connects industry leaders, investors and public-sector stakeholders to accelerate collaboration and commercial growth.

    As the Founder of the Technology Supply Chain and co-founder of the Innovation Awards, he has spent more than two decades convening influential networks that help emerging businesses find capital, strategic partners and new routes to market.

    Richard’s work spans leadership and consultancy across major organisations, alongside building membership and partnership platforms that bring universities, industry and investors into the same room – and turn conversations into practical outcomes.

    With his focus on life sciences, Richard supports organisations and people driving breakthroughs in healthcare, biotechnology, medical technology and advanced research. He is passionate about creating the conditions for transformative ideas to move from concept to real-world impact – by connecting innovators with the funding, expertise and opportunities they need to scale.

    Through Life Sciences Week, Richard is championing the UK’s world-class life sciences community and helping position it at the forefront of innovation, investment and patient outcomes.

    Amy Deakin | Chief of Staff | WM Life Sciences

    Amy Deakin

    Event Managing Director,
    Life Sciences Week
    +44 (0) 121 227 4156
    [email protected]

    Bio

    Amy Deakin is a Birmingham-based leader specialising in building partnerships and fostering innovation in the life sciences sector. With a degree in Sport and Exercise Science, Amy brings a grounded understanding of human health and performance to her work and a strong interest in the developments shaping healthcare today.

    Amy is Managing Director of Life Sciences Week, part of the One Thousand Trades Group, and also serves as Director of One Thousand Trades Events. In these roles, she convenes researchers, clinicians and industry leaders to strengthen collaboration, unlock new partnerships and help accelerate real-world innovation across the life sciences ecosystem.

    Her career spans both commercial and third-sector environments. She began in automotive design, delivering projects for Volkswagen, McLaren, Bentley and Jaguar Land Rover, before moving into the third sector with Acorns Children’s Hospice. She later joined Western Union, working as a Partnerships Manager for international payments

    An avid netballer, Amy is a committed advocate for health and wellbeing – bringing energy, clarity and connection to everything she builds, and actively involved as a participant in health related research studies.

      Award Category Voting

      Here's a list of all categories you can vote for. Simply click each category to cast your vote. Voting in each category is not mandatory, so please feel free to click just the category that interests you.

      Day you've not voted in, will be denoted with an ❌

      If you're having issues submitting the form, please ensure all the category boxes are closed and try again.

      Recognising pioneering research, technology, or therapies that are transforming healthcare and biotechnology.

      No VoteProf. Alex RichterBlack Space TechnologyAston Vision Sciences

      Celebrating an emerging leader making significant contributions to the field through research, innovation, or leadership.

      Recognising pioneering research, technology, or therapies that are transforming healthcare and biotechnology.

      No VoteShashank Chaganty – VichagLeah Vanono - PBS InnovationsKloe Avon- KZ Organics

      Honouring successful cross-sector partnerships driving advancements in life sciences, from academia to industry.

      No VoteProf Liam Grover- WMHTIAJudith Stewart- Health Innovation West MidlandsAdam McGuinness - Plug and Play

      Awarding an individual or organisation for exceptional long-term impact on the industry.

      No VoteDavid KidneyMedilink MidlandsUniversity of Birmingham

      Highlighting innovations in treatments, diagnostics, or healthcare delivery that have significantly improved patient outcomes.

      No VoteJean-Louis Duprey - Linear DiagnosticsSian Dunning - MD-TECKarim Vissangy - HoloMedix

      Your Details